primary myelofibrosis

Summary

Summary: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.

Top Publications

  1. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2009;94:141-4 pubmed publisher
  2. Chaligne R, Tonetti C, Besancenot R, Marty C, Kiladjian J, Socie G, et al. SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia. 2009;23:1186-90 pubmed publisher
  3. Kroger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113:1866-8 pubmed publisher
  4. Abdel Wahab O, Pardanani A, Rampal R, Lasho T, Levine R, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011;25:1219-20 pubmed publisher
  5. Guo Y, Xu W, Dong L, Huang N, Bi K. Progression of primary myelofibrosis to polycythemia vera: A case report. Medicine (Baltimore). 2017;96:e7464 pubmed publisher
    This case report describes the progression of primary myelofibrosis (PMF) to polycythemia vera (PV), and discuss its potential mechanisms. The patient was admitted because of abdominal discomfort and enlarged spleen for 19 months...
  6. Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C, et al. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012;53:1839-41 pubmed publisher
  7. Dombi P, Illes A, Demeter J, Homor L, Simon Z, Kellner Á, et al. [Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients]. Orv Hetil. 2017;158:901-909 pubmed publisher
    ..The Landolfi risk stratification was proven to be useful. Based on evaluated data, accuracy of diagnostic criteria and compliance to risk-adapted therapeutic guidelines are needed. Orv Hetil. 2017; 158(23): 901-909. ..
  8. Benjamini O, Jain P, Estrov Z, Kantarjian H, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012;120:2768-9 pubmed
  9. deVos T, Zachee P, Bron D, Noens L, Droogenbroeck J, Mineur P, et al. Myelofibrosis patients in Belgium: disease characteristics. Acta Clin Belg. 2015;70:105-11 pubmed publisher
    ..One hundred sixty-five (66%) of myelofibrosis patients had primary myelofibrosis and 85 (34%) had secondary myelofibrosis...

More Information

Publications84

  1. Barraco D, Cerquozzi S, Hanson C, Ketterling R, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7:e538 pubmed publisher
  2. Buxhofer Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol. 2009;82:161-3 pubmed publisher
  3. Decker M, Martinez Morentin L, Wang G, Lee Y, Liu Q, Leslie J, et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat Cell Biol. 2017;19:677-688 pubmed publisher
    Bone marrow fibrosis is a critical component of primary myelofibrosis (PMF). However, the origin of the myofibroblasts that drive fibrosis is unknown...
  4. Titmarsh G, Duncombe A, McMullin M, O Rorke M, Mesa R, de Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581-7 pubmed
    ..Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. ..
  5. Cervantes F, Mesa R, Harrison C. JAK inhibitors: beyond spleen and symptoms?. Haematologica. 2013;98:160-2 pubmed publisher
  6. Barraco D, Lasho T, Gangat N, Finke C, Elala Y, Pardanani A, et al. Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. Blood Cancer J. 2016;6:e436 pubmed publisher
  7. Mesa R, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6:79 pubmed publisher
    ..This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit. ..
  8. Tefferi A, Finke C, Lasho T, Wassie E, Knudson R, Ketterling R, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28:431-3 pubmed publisher
  9. Silver R, Barel A, Lascu E, Ritchie E, Roboz G, Christos P, et al. The effect of initial molecular profile on response to recombinant interferon-? (rIFN?) treatment in early myelofibrosis. Cancer. 2017;123:2680-2687 pubmed publisher
    ..In this phase 2 study, for the first time, the authors correlate response to rIFN? treatment with driver and HMR mutations...
  10. Haslam K, Langabeer S, Molloy K, McMullin M, Conneally E. Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation. Br J Haematol. 2014;166:800-2 pubmed publisher
  11. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197-8 pubmed publisher
  12. Pardanani A, Lasho T, Finke C, Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011;86:701-2 pubmed publisher
  13. Kusano Y, Terui Y, Ueda K, Hatake K. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib. Ann Hematol. 2016;95:1561-2 pubmed publisher
  14. Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi A, Fabris F, et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol. 2017;96:1297-1302 pubmed publisher
    ..We evaluated 253 consecutive MPN [121 essential thrombocythemia (ET), 124 polycythemia vera (PV), and 8 primary myelofibrosis (PMF)] patients in whom the JAK2V617F allele burden was available, all studied and followed (median 8...
  15. Ha J, Jeon D. Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol. 2011;86:866-8 pubmed publisher
  16. Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, et al. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leuk Res. 2017;60:18-23 pubmed publisher
    We measured plasma levels of high-sensitivity C-reactive protein (hs-CRP) in 526 subjects with primary myelofibrosis (PMF). Thirty-eight percent had an elevated hs-CRP level (≥0.3mg/dL)...
  17. Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, et al. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. Am J Hematol. 2010;85:616-9 pubmed publisher
  18. Vannucchi A, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica. 2011;96:1398-402 pubmed publisher
  19. Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuk F, Wolschke C, et al. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:872-3 pubmed publisher
  20. Hopman R, Lawrence S, Oh S. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28:1750-1 pubmed publisher
  21. Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: A case report and literature review. Medicine (Baltimore). 2017;96:e8216 pubmed publisher
    ..We report a rare case of TAFRO syndrome with histologically confirmed renal involvement...
  22. Koehler A, Hubert K, Lange T, Siebolts U, Wickenhauser C, Gopalakrishna P, et al. JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. Ann Hematol. 2015;94:1929-30 pubmed publisher
  23. Caocci G, Greco M, Delogu G, Secchi C, Perra A, Ghiani S, et al. Ruxolitinib therapy and telomere length in myelofibrosis. Blood Cancer J. 2016;6:e479 pubmed publisher
  24. Amemiya A, Ito Y, Ishibashi Y, Saito Y, Katagiri S, Suguro T, et al. BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. Rinsho Ketsueki. 2017;58:298-302 pubmed publisher
    ..Five months later, the size of her spleen was reduced. We speculated that translocation of BCR-ABL1 might have occurred in a sub-clone of the JAK2-V617F mutated tumor clone. ..
  25. Yunaev M, Hughes T, Abdul Razak M. Systemic Mastocytosis and surgery a potential disaster. ANZ J Surg. 2010;80:860-1 pubmed publisher
  26. Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med. 2014;370:1168-9 pubmed publisher
  27. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood. 2013;122:3843-4 pubmed publisher
  28. Molica M, Serrao A, Saracino R, Zacheo I, Stingone C, Alimena G, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. Ann Hematol. 2014;93:1951-2 pubmed publisher
  29. Sena I, Prazeres P, Santos G, Borges I, Azevedo P, Andreotti J, et al. Identity of Gli1+ cells in the bone marrow. Exp Hematol. 2017;54:12-16 pubmed publisher
    Bone marrow fibrosis is a critical component of primary myelofibrosis in which normal bone marrow tissue and blood-forming cells are gradually replaced with scar tissue...
  30. Vicari L, Martinetti D, Buccheri S, Colarossi C, Aiello E, Stagno F, et al. Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. Br J Haematol. 2012;159:237-40 pubmed publisher
  31. Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res. 2017;60:31-35 pubmed publisher
    ..4%) and non-hematologic toxicity in two patients (14.3%). Although combination therapy did not lead to increased hematologic response per IWG-MRT criteria, hematologic stabilization was observed and may be clinically useful. ..
  32. Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood. 2017;130:115-125 pubmed publisher
    ..Ruxolitinib is in late-phase clinical trials in essential thrombocythemia, in which it could fill an important void for patients with troublesome symptoms. ..
  33. Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, et al. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma. Hematology. 2015;20:203-7 pubmed publisher
    ..Although palliative irradiation of splenic lesions in patients with MF or NHL is safe and effective, optimal irradiation doses may differ for MF and NHL. More cases need to be accumulated to elucidate these differences. ..
  34. Rontauroli S, Norfo R, Pennucci V, Zini R, Ruberti S, Bianchi E, et al. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget. 2017;8:21380-21397 pubmed publisher
    b>Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, involving especially the megakaryocyte lineage...
  35. Guo B, Allcock R, Mirzai B, Malherbe J, Choudry F, Frontini M, et al. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations. Am J Pathol. 2017;187:1512-1522 pubmed publisher
    ..These findings show that genomic abnormalities are present in megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow fibrosis. ..
  36. Bauermeister D. Quantitation of bone marrow reticulin--a normal range. Am J Clin Pathol. 1971;56:24-31 pubmed
  37. Pardanani A, Brown P, Neben Wittich M, Tobin R, Tefferi A. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol. 2010;85:715-6 pubmed publisher
  38. Matsuura S, Patterson S, Lucero H, Leiva O, Grant A, Herrera V, et al. In vivo magnetic resonance imaging of a mouse model of myelofibrosis. Blood Cancer J. 2016;6:e497 pubmed publisher
  39. Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, et al. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol. 2017;147:444-452 pubmed publisher
    To compare the mutational profiles of patients with primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocytosis (ET)...
  40. Tefferi A, Mudireddy M, Gangat N, Hanson C, Ketterling R, Pardanani A, et al. Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. Am J Hematol. 2017;92:1187-1192 pubmed publisher
    ..Leukemia-free survival was predicted by very high risk karyotype. The observations from the current study might help identify appropriate candidates for splenectomy in MF. ..
  41. Bose P, Abou Zahr A, Verstovsek S. Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs. 2017;26:723-734 pubmed publisher
    ..Selective JAK1 inhibition alone is unlikely to succeed in myelofibrosis. In these circumstances, rational ruxolitinib-based combinations may represent the best way forward. ..
  42. Ohba R, Usui N, Ito Y, Yamauchi H, Machishima T, Ishii H, et al. Myelodysplastic syndrome with myelofibrosis in which azacitidine therapy was effective and cord blood transplantation was carried out. Rinsho Ketsueki. 2017;58:601-606 pubmed publisher
    ..While treatment prior to allogeneic SCT of MDS-F has not been established, in the present case, the hematological improvement brought about by AZA likely contributed to the patient's positive response to UCBT. ..
  43. Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J. 2015;5:e360 pubmed publisher
  44. Erba B, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, et al. Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis. Am J Pathol. 2017;187:1879-1892 pubmed publisher
    b>Primary myelofibrosis is characterized by the development of fibrosis in the bone marrow that contributes to ineffective hematopoiesis...
  45. Kusano Y, Terui Y, Ueda K, Hatake K. Epstein-Barr virus gastric ulcer associated with ruxolitinib. Ann Hematol. 2016;95:1741-2 pubmed publisher
  46. Kreuziger L, Carlson M, Mesa H, Gupta P. Perinephric extramedullary haematopoiesis in primary myelofibrosis. Br J Haematol. 2012;157:157 pubmed publisher
  47. Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A, et al. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. Br J Haematol. 2016;173:938-40 pubmed publisher
  48. Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28:449-51 pubmed publisher
  49. Hobbs G, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017;31:613-626 pubmed publisher
    ..The Food and Drug Administration approved the JAK1/JAK2 inhibitor, ruxolitinib, for the treatment of myelofibrosis and polycythemia vera. Additional JAK2 inhibitors are currently in advanced phased clinical trials. ..
  50. Montemayor Garcia C, Coward R, Albitar M, Udani R, Jain P, Koklanaris E, et al. Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia. Transfusion. 2017;57:2136-2139 pubmed publisher
    ..Detection of mixed-field reactions and investigation of discrepant blood typing results are important for proper transfusion support of these patients and can provide useful surrogate markers of myeloproliferative disease progression. ..
  51. Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92:885-891 pubmed publisher
    The 2016 revised WHO criteria for the diagnosis of pre-fibrotic/early primary myelofibrosis (pre-PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate ..
  52. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227-3236 pubmed publisher
    ..of the World Health Organization (WHO) classification of myeloproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF): prefibrotic/early (pre-PMF) and overt fibrotic (overt PMF) phase...
  53. Barraco D, Elala Y, Lasho T, Begna K, Gangat N, Finke C, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6:e415 pubmed publisher
  54. Chen Y, Lee C, Pei S. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56:1528-9 pubmed publisher
  55. Daver N, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma. 2015;56:279-80 pubmed publisher
  56. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leuk Lymphoma. 2014;55:195-7 pubmed publisher
  57. Shah R, Munson M, Wierenga K, Pokala H, Newburger P, Crawford D. A novel homozygous VPS45 p.P468L mutation leading to severe congenital neutropenia with myelofibrosis. Pediatr Blood Cancer. 2017;64: pubmed publisher
    ..Bone marrow transplantation, complicated by early graft failure rescued with stem cell boost, led to resolution of the hematopoietic phenotype. ..
  58. Tefferi A, Lasho T, Tischer A, Wassie E, Finke C, Belachew A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124:2465-6 pubmed publisher
  59. Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94:519-20 pubmed publisher
  60. Saeed I, McLornan D, Harrison C. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Rev Hematol. 2017;10:617-625 pubmed publisher
    ..The side effect profile, in the most, is predictable and manageable with high degrees of clinical surveillance and dose modifications. ..
  61. Stubig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28:1736-8 pubmed publisher
  62. Verstovsek S, Mesa R, Salama M, Li L, Pitou C, Nunes F, et al. A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk Res. 2017;61:89-95 pubmed publisher
    ..implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia...
  63. Dutta A, Hutchison R, Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-?1 and Cxcl12 pathways. Blood. 2017;130:920-932 pubmed publisher
    ..Together, these findings demonstrate that expression of Hmga2 cooperates with Jak2V617F in the pathogenesis of MF. ..
  64. Rumi E, Passamonti F, Arcaini L, Bernasconi P, Elena C, Pietra D, et al. Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant. 2010;45:798-800 pubmed publisher
  65. Newberry K, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017;130:1125-1131 pubmed publisher
    ..These findings underscore the need for novel therapies and suggest that clonal evolution or decreasing platelet counts while on ruxolitinib therapy may be markers of poor prognosis. ..
  66. Yao Q, Zhou J, Gale R, Li J, Li L, Li N, et al. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. Hematology. 2015;20:517-22 pubmed publisher
    ..recently identified in a substantial proportion of persons with essential thrombocythemia (ET) and with primary myelofibrosis (PMF) without JAK2(V617F)...
  67. Gwaltney C, Paty J, Kwitkowski V, Mesa R, Dueck A, Papadopoulos E, et al. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res. 2017;59:26-31 pubmed publisher
    ..The MFSAF v4.0, for which there are 24-h and 7-day recall formats, will be maintained and licensed by the Critical Path Institute and made publicly available for use in future clinical trials. ..
  68. Leiva O, Ng S, Chitalia S, Balduini A, Matsuura S, Ravid K. The role of the extracellular matrix in primary myelofibrosis. Blood Cancer J. 2017;7:e525 pubmed publisher
    b>Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis...
  69. Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P, et al. Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms. Ann Hematol. 2016;95:1559-60 pubmed publisher
  70. Salama M, Swierczek S, Tashi T, Warby C, Reading N, Prchal J. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood. 2014;124:1691-2 pubmed publisher
  71. Campanelli R, Rosti V, Fois G, Bonetti E, Barosi G, Massa M. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol. 2014;42:244-6 pubmed publisher
  72. Laborde R, Patnaik M, Lasho T, Finke C, Hanson C, Knudson R, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia. 2013;27:2100-2 pubmed publisher
  73. Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, et al. Quantification of JAK2V617F mutation by next-generation sequencing technology. Am J Hematol. 2013;88:536-7 pubmed publisher
  74. Abdel Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25:1200-2 pubmed publisher
  75. Mesa R, Silverstein M, Jacobsen S, Wollan P, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61:10-5 pubmed
    ..4%. This was significantly worse than for age-matched controls (P < 0.001). This study provides population-based incidence and comparative survival figures in ET and AMM. ..